Loading…
← CockpitCompetitor Analysis › CTY City Therapeutics, Inc.Open in the cockpit ↗

City Therapeutics, Inc.CTYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.

≈ A smaller, earlier-stage Alnylam
Mkt cap
$861M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$5.11M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.2%
Hurdle
n/a
no reverse DCF
Close · USD$16.64
1D-4.9%
1W-2.2%
1M-20.1%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %14.3%
52w lowhigh30.3% off high

What City Therapeutics does

Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.

Pre-revenue: funds early-stage trials from investor capital, including its October 2026 Nasdaq IPO. RNAi medicines switch off a gene's messenger RNA to cut production of a harmful protein, and the lead drug targets Factor XI, a clotting protein, as an anticoagulant. Co-founder John Maraganore, former Alnylam CEO, is executive chair; Bausch + Lomb and Biogen are research partners.

In one line: A smaller, earlier-stage Alnylam.

Products and services

  • CITY-FXI (Factor XI anticoagulant)
  • CITY-RBP4 (Stargardt disease, geographic atrophy)
  • CITY-TFR2 (anemia of chronic disease)

Customers

  • Patients needing anticoagulation
  • Patients with eye disease
  • Patients with anemia of chronic disease

Where it sits in the supply chain

  • Biotechnology
  • Clinical-stage drug developer
  • RNA interference (RNAi) therapeutics

What could go right

  • Research partners Bausch + Lomb and Biogen
  • Factor XI anticoagulant Phase 1 safety data

What could go wrong

  • Early stage with no approved product
  • Crowded Factor XI field with large pharma rivals

Moat: narrow (IP / patents, process know-how). Proprietary RNAi trigger designs and delivery conjugates; founders have RNAi drug-development experience.

Headquarters: Massachusetts, United States · Founded: 2023

Named competitors

City Therapeutics at a glance

Size City Therapeutics (CTY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $861M, the 2319th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.64 on 18 Nov 2026.

Growth Revenue grew 388.2% over the last twelve months (peer median +1.4%); the operating margin is -441.8% (peer median 1.4%).

Short interest Short interest is 1.6% of the free float (30 Oct 2026).

City Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$13.6M$2.78M
Revenue growth—+388%—
Gross profitn/a$12.4M$2.35M
EBITDAn/a-$58.8M-$28.7M
Net incomen/a-$58.5M-$27.8M
Free cash flown/a-$44.0M-$23.9M
Capital expendituren/a$2.40M$3.54M
Total debtn/a$212M$167M

Quarterly statements and history in the cockpit →

City Therapeutics competitors and peer comparison

Head to head with its named competitors (CTY vs ALNY vs ARWR vs IONS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
City Therapeutics CTY$861Mn/a+388%-442%n/an/a
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%3.9×0.5%
Arrowhead Pharmaceuticals ARWR$6.09B-44%-46%-157%14.0×n/a
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How City Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

City Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCTYPeer medianRank in peer set
1-month return-20.1%-10.5%4th lowest of 21
Distance from 52-week high-30.3%-43.7%5th highest of 21
Revenue growth (TTM)+388.2%+1.4%highest of 19
Operating margin-441.8%1.4%4th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a

Questions

Who are City Therapeutics's main competitors?
Named competitors: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Ionis Pharmaceuticals (IONS), Regeneron (REGN), Bristol Myers Squibb (BMY). The cockpit's measured peer set (industry) also includes Kaken Pharmaceutical (4521.T), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.